Particle.news
Download on the App Store
9 ARTICLES
·
2w ago

VDR Gene Variant Tied to 19% Lower Diabetes Risk With High-Dose Vitamin D3

A post hoc D2d analysis suggests vitamin D’s benefit depends on a common receptor genotype.

Image
Image
Image
The study by Martineau et al provides the most robust evidence yet that vitamin D has benefits beyond bone and muscle health, and could have major implications for public health policy.

Overview

  • The JAMA Network Open genetic analysis, published Thursday, found that 4,000 IU of vitamin D3 daily cut progression to type 2 diabetes by 19% in prediabetic adults with the ApaI AC or CC vitamin D receptor genotypes.
  • Participants with the ApaI AA genotype, about 30% of the cohort, showed no benefit, consistent with the D2d trial’s original null result in the full intention-to-treat population.
  • The genetic subanalysis drew on 2,098 consented D2d participants followed for a median 2.5 years and focused on common vitamin D receptor variants including ApaI, BsmI, and FokI.
  • Prior D2d work linked higher blood 25-hydroxyvitamin D levels of roughly 40–50 ng/mL to lower diabetes risk, and vitamin D’s receptor on pancreatic insulin-producing cells offers a plausible biological pathway.
  • The authors called the finding exploratory and urged replication and genotype-stratified trials, and experts warned against self-prescribing high doses given guideline targets of 600–800 IU for adults and a 4,000 IU upper limit.